SXTP 60 Degrees Pharmaceuticals Inc

$SXTP Dont worry $SLS trades at 2.3 Billion market cap with Zero fda approved drug. We have fda approved drug, 2.6million share float, and data due Tues. Data chasers will come

$SXTP 2 put in perspective $SLS trades at 2.3 Billion market with No fda approved drug. We have fda approved drug with data tomorrow

$SXTP No significant run before data release. If data is good, there will not be sell the news movement.

$SXTP Just a wild guess outside of traders possibly jumping in, I wouldn't be surprising if Knight Therapuetics was buying raising their stake to own more shares so to reduce the amount of shares needed for a takeover bid. Just a gut feeling. Good luck to all next week.

$SXTP last time red chip was on this was Jan. when it ran huge will be on CNBC and Bloomberg over the weekend, also presenting data Tuesday Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.

$SXTP announces interim data release and KOL webinar on Oct 6 for its severe babesiosis study.

You might want to check as he is bringing to light some very bullish intel on $SXTP . There's a plot involving a takeover by Knight Therapeutics. Market cap is ridiculous and the stock price has been pushed from the bottom. 🪖🫡☝️http://www.stocktwits.com/NolAsrtormZ

$SXTP Shouldn't we already be trading at this valuation without drug approved like SLS 🤣🤣🤣🤑🤑🤑 By the way share float 2.6million Market cap below 5 million

$SXTP 60 degrees pharmaceuticals plans january 2027 hospitalized babesiosis data readout; will seek pre-snda meeting with fda

$SXTP Look for the latest 8-k report. News are there. No interim data for today, study stays blinded. I'm out until January.

$SXTP provides an updated investor presentation and a press release on its Jan 2027 hospitalized babesiosis data readout.

$SXTP Who saw that short spike up to 1.82 but than got hammered down back to 1.55?? There trying to hold it down for now

$SXTP added the dip, presenting data Tuesday Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026

$SXTP I don’t see this as a flip for Knight Therapeutics but rather a long term investment or more likely a takeover candidate with any positive FDA approval for the drug. We will find out next week.

$SXTP it’s almost breaking out. I bought some at 1.23 but I prefer it to close above 1.33 for breakout to confirm

$SXTP Someone really wanted to hop in. Tomorrow might be the data release day. Any good thoughts if Interim data is success?

$SXTP - Knight Therapeutics may acquire SXTP MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 53%. “We’re honored to be recognized as one of Canada’s Top Growing Companies by Report on Business for the sixth consecutive year,” said Samira Sakhia, President and CEO of Knight. “This recognition belongs to our team across Canada and Latin America. Their focus and disciplined execution continue to drive Knight's growth. We remain committed to bringing innovative products to physicians and improving the health of the patients they serve. With over 50 product launches completed or planned across Canada and Latin America, we are well positioned to build on this momentum.”